Reports Q3 revenue $12.877M, consensus $12M. “In September, we successfully transitioned the commercialization program for AYON from an effective soft launch targeting key regions to a full U.S. program. Initial feedback from leading board-certified plastic and cosmetic surgeons continues to be overwhelmingly positive, with several of them contributing at workshops and clinical symposia that drove strong engagement and resulted in pre-orders for the AYON. While we are still in the early stages of ramping up the broader commercial program, I am excited to announce that we reported a 19% increase in Surgical Aesthetics revenue for the third quarter of 2025,” said Charlie Goodwin, President and Chief Executive Officer.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on APYX:
- Is APYX a Buy, Before Earnings?
- Hold Rating for Apyx Medical Amid Promising Ayon System and Challenging Market Conditions
- Apyx Medical submits FDA 510k to U.S. FDA for label expansion of AYON
- Needham medtech & diagnostics analysts hold analyst/industry conference call
- Apyx Medical’s Renuvion APR System: Promising Results in Facelift Surgery Study